AMG National Trust Bank Has $4.72 Million Stake in Astrazeneca Plc $AZN

AMG National Trust Bank lowered its position in shares of Astrazeneca Plc (NYSE:AZN) by 48.8% during the first quarter, HoldingsChannel reports. The fund owned 23,921 shares of the company’s stock after selling 22,793 shares during the quarter. AMG National Trust Bank’s holdings in Astrazeneca were worth $4,716,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Legacy Capital Group California Inc. bought a new position in Astrazeneca in the first quarter valued at about $351,000. J. Safra Sarasin Holding AG grew its holdings in shares of Astrazeneca by 7,317.7% during the first quarter. J. Safra Sarasin Holding AG now owns 168,752 shares of the company’s stock worth $32,658,000 after purchasing an additional 166,477 shares during the last quarter. Avion Wealth grew its holdings in shares of Astrazeneca by 166.2% during the first quarter. Avion Wealth now owns 197 shares of the company’s stock worth $38,000 after purchasing an additional 123 shares during the last quarter. LGT Fund Management Co Ltd. increased its stake in shares of Astrazeneca by 160.3% in the first quarter. LGT Fund Management Co Ltd. now owns 103,991 shares of the company’s stock valued at $20,203,000 after buying an additional 64,033 shares during the period. Finally, Anchor Investment Management LLC acquired a new position in shares of Astrazeneca in the first quarter valued at approximately $86,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Key Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Negative Sentiment: AstraZeneca is facing investor-law-firm investigations after the Wainua trial miss and the related stock drop, adding headline risk and potential litigation over alleged securities claims. Article Title
• Negative Sentiment: HSBC downgraded AstraZeneca and lowered its price target after the Wainua setback, saying the failure removes a central support for the company’s bullish outlook and leaves a tougher catalyst path ahead. Article Title
• Negative Sentiment: A second investor alert from Levi & Korsinsky highlighted the Wainua phase 3 miss and encouraged shareholders to seek recovery of losses, reinforcing the negative sentiment around the trial failure. Article Title
• Neutral Sentiment: UBS remained constructive ahead of AstraZeneca’s second-quarter results, saying it expects solid earnings but limited room for full-year guidance increases. Article Title
• Positive Sentiment: AstraZeneca also announced an exclusive global licensing deal for a lung-cancer pill from China’s Dizal Pharmaceutical, paying $600 million upfront with up to $900 million in milestones. The deal could strengthen its oncology pipeline and supports longer-term growth. Article Title

Astrazeneca Stock Down 2.9%

Shares of NYSE AZN opened at $164.55 on Wednesday. The company’s 50 day moving average price is $183.04 and its 200-day moving average price is $188.58. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. Astrazeneca Plc has a 52-week low of $137.23 and a 52-week high of $212.71. The company has a market capitalization of $255.21 billion, a P/E ratio of 24.71, a price-to-earnings-growth ratio of 1.37 and a beta of 0.24.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The company had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Equities analysts forecast that Astrazeneca Plc will post 10.28 earnings per share for the current year.

Wall Street Analyst Weigh In

AZN has been the subject of a number of research reports. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $211.00.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.